The FDA has prioritized review of C2N’s blood test for amyloid-β. A pivotal clinical trial will correlate the test with amyloid PET scans.
An interim analysis predicted the antibody would not slow Alzheimer’s progression; a crenezumab trial in autosomal-dominant AD is continuing.
Reducing systolic blood pressure staves off cognitive decline, but what about dementia?
A periodontal pathogen found in human brains triggers AD pathology in mice. Will an antibiotic stave off dementia?
Frail people may be more likely to have Aβ plaques and neurofibrillary tangles; when they do, they are more likely to have dementia. Physical activity correlated with better global cognition, regardless of brain pathology.
Studies in mice and humans show that sleep suppresses extracellular tau and slows its spread.
Ever wonder why it’s so easy to nod off in a hammock? Turns out swaying back and forth improves sleep and even enhances memory in people.
Are high-molecular-weight, multi-protease complexes cellular Aβ factories?
In familial Alzheimer’s disease, rise in NfL in the blood precedes disease onset by 16 years.
In neurons derived from FTD patients, microtubules distort the nucleus, warping its normally rounded membrane and disrupting communication with the cytoplasm.
Stakeholders have until February 11 to comment on draft FDA guidance for biomarker qualification.
Two independent studies find that loss of nuclear TDP-43 leads to mis-splicing of stathmin 2, an essential protein for axon growth and repair.
A leaky blood-brain barrier in the hippocampus correlated with cognitive impairment, independently of other vascular risk factors or Alzheimer’s pathology.
Levels of irisin are lower in brain and CSF of AD patients. Upping expression in mice protected them from synaptic deficits and memory problems.
Researchers characterize widespread cerebral amyloid angiopathy and cortical plaques found in three living people who received dural grafts as children.